IMMIX BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
IMMIX BIOPHARMA, INC. (IMMX) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 3.43 million shares for the 12-month period ending 2025-12-31, per its 10-K/A filed 2026-03-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2026-03-27
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-12-31 was 490.20K shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2023-12-31 was 0.00 shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-12-31 was 0.00 shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-09-30 was 0.00 shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2025 was 3.43M shares.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2023 was 1.91M shares, a 5975.11% increase from fiscal 2022.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2022 was 31.50K shares, a 91.39% decline from fiscal 2021.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2021 was 366.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month |
|---|---|---|---|---|
| 2025-12-31 | 490.20K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | 3.43M shares 10-K/A · filed 2026-03-27 | ||
| 2025-09-30 | 2.94M shares 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | 1.91M shares 10-K · filed 2025-03-25 | ||
| 2023-09-30 | 1.91M shares 10-Q · filed 2023-11-13 | |||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-29 | 0.00 shares derived: sum of 3 quarters · filed 2024-03-29 | 31.50K shares 10-K · filed 2024-03-29 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-09 | 31.50K shares 10-Q · filed 2022-11-09 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 31.50K shares 10-Q · filed 2022-08-12 | ||
| 2022-03-31 | 31.50K shares 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | 366.00K shares 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |